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Abstract
Background: Ineffective risk stratification can delay diagnosis of serious disease in patients with hematuria. We
applied a systems biology approach to analyze clinical, demographic and biomarker measurements (n = 29)
collected from 157 hematuric patients: 80 urothelial cancer (UC) and 77 controls with confounding pathologies.
Methods: On the basis of biomarkers, we conducted agglomerative hierarchical clustering to identify patient and
biomarker clusters. We then explored the relationship between the patient clusters and clinical characteristics using
Chi-square analyses. We determined classification errors and areas under the receiver operating curve of Random
Forest Classifiers (RFC) for patient subpopulations using the biomarker clusters to reduce the dimensionality of the
data.
Results: Agglomerative clustering identified five patient clusters and seven biomarker clusters. Final diagnoses
categories were non-randomly distributed across the five patient clusters. In addition, two of the patient clusters
were enriched with patients with ‘low cancer-risk’ characteristics. The biomarkers which contributed to the
diagnostic classifiers for these two patient clusters were similar. In contrast, three of the patient clusters were
significantly enriched with patients harboring ‘high cancer-risk” characteristics including proteinuria, aggressive
pathological stage and grade, and malignant cytology. Patients in these three clusters included controls, that is,
patients with other serious disease and patients with cancers other than UC. Biomarkers which contributed to the
diagnostic classifiers for the largest ‘high cancer- risk’ cluster were different than those contributing to the classifiers
for the ‘low cancer-risk’ clusters. Biomarkers which contributed to subpopulations that were split according to
smoking status, gender and medication were different.
Conclusions: The systems biology approach applied in this study allowed the hematuric patients to cluster
naturally on the basis of the heterogeneity within their biomarker data, into five distinct risk subpopulations. Our
findings highlight an approach with the promise to unlock the potential of biomarkers. This will be especially
valuable in the field of diagnostic bladder cancer where biomarkers are urgently required. Clinicians could interpret
risk classification scores in the context of clinical parameters at the time of triage. This could reduce cystoscopies
and enable priority diagnosis of aggressive diseases, leading to improved patient outcomes at reduced costs.
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tion, urothelial cancer, proteinuria
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Background
The number of patients presenting with hematuria is
progressively increasing in our aging population and the
diagnosis of serious diseases in some of these patients
can be delayed when triage is ineffective [1]. Therefore,
novel alternative risk stratification approaches are
needed [2].
Hematuria, that is, the presence of blood in urine, is a
presenting symptom for a variety of diseases. The final
diagnosis for hematuric patients ranges from no diagnosis,
through benign conditions including urinary infection,
stone disease, benign prostate enlargement (BPE) to renal
diseases and malignant causes. Urothelial cancer (UC), the
most common malignancy in hematuric patients, is the
fourth most common cancer in men and was the esti-
mated cause of death in 150,200 people worldwide in 2008
[3]. Bladder cancer is associated with many risk factors [2].
Smoking increases the risk of UC fourfold and cessation of
smoking is associated with a decreased risk [2].
The risk parameters that are currently used to tailor
follow-up for patients diagnosed with UC, include
pathological parameters, that is, grade, stage and asso-
ciated carcinoma in situ (CIS), together with resistance
to Bacille Calmette-Guerin treatment. At the time of
diagnosis, approximately 70% of patients diagnosed with
UC have tumors that are pathologically staged as pTa,
pT1 or CIS, that is, non-muscle invasive (NMI) disease.
The remaining patients present with muscle invasive UC
(MI UC) which has a high-risk of progression to a more
life threatening disease [2,4]. Unfortunately, it is not
always possible to predict correctly the outcome for
patients. This is largely attributable to the molecular
heterogeneity within tumors which means that a spec-
trum of outcomes, spanning from negligible risk to life
threatening prognosis, exist within the same pathological
classification. For this reason, all patients with NMI dis-
ease have frequent surveillance cystoscopies and those
with MI UC have radiological surveillance for lymph
node recurrence or distant metastasis [2].
Cystoscopy is the gold standard for the detection and sur-
veillance of NMI UC [2]. However, this procedure is costly
and invasive for the patient. Further, it requires a significant
clinical input and has its own shortcomings [2,5]. Cytology,
another diagnostic test for bladder cancer, detects the pre-
sence of malignant cells in urine. Although cytology has
high specificity, it has insufficient sensitivity to stand alone
as a diagnostic test for UC in patients presenting with
hematuria [2]. Three diagnostic bladder cancer biomarkers,
Nuclear Matrix Protein 22 [6], Bladder Tumor Antigen
(BTA) [7] and Fibrinogen Degradation Product [8] have
Food and Drug Administration (FDA) approval. However,
these biomarkers are not in use in routine practice as
diagnostic biomarkers for UC because of their limited
specificity. There is, therefore, a strong clinical need for
urine-based tests which can at least riskstratify and, if possi-
ble, be diagnostic in hematuric patients [2].
Researchers often combine multiple tests, genes or bio-
markers [9-11]. However, it is not possible to predict
intuitively how multiple measurements will collectively
reflect the underlying biological heterogeneity in complex
diseases, such as UC. Complex diseases consist of multi-
ple components which interact to produce emergent
properties that the individual components do not pos-
sess. The difficulties to date with large amounts of patient
biomarker data are that they do not manage or group all
patients in a clinically meaningful way. Systems biology is
based on the assumption that interactions among mole-
cular components need to be integrated in order to
obtain a functional understanding of physiological prop-
erties [12,13]. In this paper we used a systems approach,
that is, clustering and Random Forests Classification
(RFC), to analyze a comprehensive dataset collected from
157 hematuric patients: 80 patients with UC and 77 con-
trols with a range of confounding pathologies.
When we allowed the patients to cluster naturally on
the basis of their individual biomarker profiles this
resulted in five patient clusters with a non-random dis-
tribution of risk characteristics. Three of these patient
clusters were enriched with patients with cancer-risk
characteristics. The remaining two patient clusters were
enriched with patients with non-cancer characteristics.
Methods
Patient information and samples
We analyzed data collected during a case-control study
approved by the Office for Research Ethics Committees
Northern Ireland (ORECNI 80/04) and reviewed by hospi-
tal review boards. The study was conducted according to
the Standards for Reporting of Diagnostic Accuracy
(STARD) guidelines [14,15]. Written consent was obtained
from patients with hematuria who had recently undergone
cystoscopy or for whom cystoscopy was planned. Patients
(n = 181) were recruited between November 2006 and
October 2008 [9]. A single consultant pathologist under-
took a pathological review of the diagnostic slides for all
bladder cancer patients. The following patients were
excluded from our analyses: 19 patients with a history of
bladder cancer who were disease-free when sampled; one
patient who had adenocarcinoma; one patient who had
squamous cell carcinoma; and three patients ≥ 85 years
old. We, therefore, analyzed data from 157 patients. A sin-
gle consultant cytopathologist reviewed the cytology from
74 bladder cancer and 65 control patients. There were
insufficient cells for diagnosis in 18/157 patients.
The final diagnosis for each of the 157 patients was
based on history, physical examination, urinary tract
radiological and endoscopy findings and the pathological
reports relating to biopsy or resection specimens. For
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36/157 (23%) patients, it was not possible to identify the
underlying cause for hematuria, even after detailed
investigations, including cystoscopy and radiological
imaging of the upper urinary tract. These patients were
assigned to the ‘no diagnosis’ category. The remaining
patients were assigned into one of the following six cate-
gories: ‘benign pathologies’, ‘stones/inflammation’, ‘BPE’,
‘other cancers’, ‘NMI UC’ or ‘MI UC’. For analyses pur-
poses, we grouped ‘no diagnosis’, ‘benign pathologies’,
‘stones/inflammation’ and ‘BPE’ together as non-life
threatening diagnoses, and grouped ‘other cancers’,
‘NMI UC’ and ‘MI UC’ as life threatening diagnoses
(Table 1).
Biomarker measurement
Biomarker measurements were undertaken on anon-
ymized samples at Randox Laboratories Ltd. For each
patient, we measured 29 biomarkers; 26 were measured in
triplicate (Table 2). Samples were stored at -80°C for a
maximum of 12 months prior to analysis. Creatinine levels
(µmol/L) were measured using a Daytona RX Series Clini-
cal Analyzer (Randox) and Osmolarity (mOsm) was mea-
sured using a Löser Micro-Osmometer (Type 15) (Löser
Messtechnik, Germany). Total protein levels (mg/ml) in
urine were determined by the Bradford assay A595nm
(Hitachi U2800 spectrophotometer) using bovine serum
albumin as the standard. We classified proteinuria as total
urinary protein >0.25mg/ml [16]. Eighteen biomarkers in
urine, and carcino-embryonic antigen (CEA) and free
prostate specific antigen (FPSA) in serum were measured
using Randox Biochip Array Technology (Randox
Evidence © and Investigator ©), which are multiplex sys-
tems for protein analysis [17]. An additional four biomar-
kers were measured using commercially available ELISAs.
Epidermal growth factor (EGF) and the matrix metallopro-
teinase 9 neutrophil-associated gelatinase lipocalin
(MMP9-NGAL) complex were measured using in-house
ELISAs (Table 2).
Data representation
Data were represented by a matrix X with 157 rows and 29
columns, for example, X(3,5) contained the measurement
for patient number 3 and biomarker number 5. In order
to simplify the notation, we denoted by X(j,) the 29 dimen-
sional feature vector for patient j and by X(,k) the 157
dimensional feature vector for biomarker k.
Identification of patient clusters
Patients were separated into clusters according to the
similarities of their 29 biomarkers using a hierarchical
clustering with a Canberra distance and a Mcquitty clus-
tering [18]. Therefore, each patient’s profile vector was
derived from the levels of the 29 biomarkers in their sam-
ples, for example, X(i,) as a profile vector for patient i.
To demonstrate the robustness of the observed clusters,
we repeated the same analysis 100 times using only a
bootstrap subset of the patients to conduct the clustering.
Chi-square tests
We explored the distribution of final diagnoses and known
cancer risk characteristics across the patient clusters. We
then constructed five cross-tables in which the patient
clusters were listed in rows; and the final diagnosis
Table 1 Final diagnosis categories.
Individual patient final
diagnosis
n Final diagnosis
category
Group Total
No diagnosis 36 No diagnosis NLT 36
Category total 36
Fistula 1 Benign NLT
Endometriosis 1 Benign NLT
Trauma 1 Benign NLT
Renal trauma 1 Benign NLT
Renal cyst 1 Benign NLT
Squamous Metaplasia 1 Benign NLT
Category total 6
Stone 9 Stones/inflammation NLT
Stone(s) with inflammation 2 Stones/inflammation NLT
Stone with UTI 1 Stones/inflammation NLT
Urinary tract infection 1 Stones/inflammation NLT
Inflammation 4 Stones/inflammation NLT
Category total 17
BPE with stone 2 BPE NLT
BPE 10 BPE NLT
Category total NLT 12
Renal cell carcinoma with
BPE
1 Other cancers LT
Renal cell carcinoma 2 Other cancers LT
Prostate cancer 3 Other cancers LT
Category total 6
UC kidney ureter 1 NMI UC LT
NMI TCC with stone 2 NMI UC LT
NMI TCC with BPE 1 NMI UC LT
NMI TCC 58 NMI UC LT
Category total 62
MI UC with stone 2 MI UC LT
MI UC with BPE 2 MI UC LT
MI UC 14 MI UC LT
Category total 18
TOTAL 157
The final diagnosis was determined individually for each patient. The decision
was based on history, physical examination, urinary tract radiological and
endoscopy findings and also the pathological reports relating to biopsy or
resection specimens. Based on their final diagnosis, each patient was assigned
to one of the seven final diagnosis categories. For statistical purposes these
categories were split into non-life threatening (NLT) or life threatening (LT)
groups. BPE, benign prostate enlargement; MI muscle invasive; n, number;
NMI, non-muscle invasive; TCC transitional cell carcinoma; UC, urothelial
cancer; UTI, urinary tract infection.
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category, absence/presence of proteinuria, pathological
stage, pathological grade, or absence/presence of mali-
gnant cytology, was listed in columns. When the number
of observed counts was <5 in >80% of cells in any of
these tables, we merged groups as previously described
(Table 1), prior to undertaking Chi-square analysis.
Identification of biomarker clusters
To allow us to exploit the full complement of biomarker
data for subsequent classifications, we conducted hierarch-
ical clustering to identify substructures within the 29 bio-
markers themselves. That means for each biomarker k we
used X(,k) as a profile vector to conduct an agglomerative
clustering for the 29 biomarkers. Thus each biomarker’s
profile vector was based on the levels of the biomarker
measured in each of the 157 patients. On the assumption
that biomarkers within individual biomarker clusters
would be similar to each other and, hence, contain redun-
dant biological information about patients, we subse-
quently used one biomarker from each cluster for the
classification of individual patient clusters and patient
subpopulations, as described in the next section.
Random forest classification (RFC)
As our classification method, we used RFC which is an
ensemble method consisting of multiple decision trees
which, taken together, can be used to assign each patient
into either of two categories. The overall classification of
Table 2 Biomarkers.
Biomarker Units Analysis Clinical application
Protein mg/ml Bradford Assay Kidney disease
Creatinine µmol/L Daytona RX Series Clinical Analyzer (Randox) Kidney disease
Osmolality mOsm Löser Micro-Osmometer (Type 15) (Löser Messtechnik,
Germany)
Kidney disease
Bladder tumor antigen (BTA) U/ml ELISA (Polymedco) UC diagnosis
Carcino-embryonic antigen (CEA) (serum) ng/ml BAT Monitoring colorectal
cancer
‡Cytokeratin 18 (CK18) ng/ml ELISA (USCNLIFE Science & Technology Co. Ltd) N/A
C-reactive protein (CRP) ng/ml BAT Acute inflammation/
infection
D-dimer ng/ml BAT Pulmonary embolus
Epidermal growth factor (EGF) pg/ml ELISA (in house) UC prognosis
‡FAS pg/ml ELISA (Raybio, Inc) N/A
‡Hyaluronidase (HA) ng/ml ELISA (Echelon Biosciences Inc) N/A
Interleukin-1a (IL-1 a) pg/ml BAT N/A
Interleukin-1b (IL-1 b) pg/ml BAT N/A
Interleukin-2 (IL-2) pg/ml BAT N/A
Interleukin-4 (IL-4) pg/ml BAT N/A
Interleukin-6 (IL-6) pg/m BAT N/A
InterleukinL-8 (IL-8) pg/ml BAT N/A
Monocyte chemoattractant protein-1 (MCP-1) pg/ml BAT N/A
Matrix metalloproteinase 9 (MMP9) ng/ml BAT N/A
MMP-9NGAL complex N/A ELISA (in house) N/A
Neutrophil-associated gelatinase lipocalin
(NGAL)
ng/ml BAT Kidney disease
Neuron specific enolase (NSE) ng/ml BAT
Free prostate specific antigen (FPSA) (serum) ng/ml BAT Prostate cancer
Thrombomodulin (TM) ng/ml BAT N/A
Tumor necrosis factor a (TNFa) pg/ml BAT N/A
Soluble tumor necrosis factor receptor 1
(sTNFR1)
ng/ml BAT N/A
Soluble tumor necrosis factor receptor 2
(sTNFR2)
ng/ml BAT N/A
Vascular endothelial growth factor (VEGF) pg/ml BAT angiogenesis
Von Willeband factor (vWF) IU/ml BAT N/A
Biomarkers were measured in triplicate except for those marked ‡ for which only a single analysis was undertaken. Twenty of the 29 biomarkers were measured
using Biochip Array Technology (BAT) which facilitates the simultaneous analyses of multiple proteins [17]. ELISA, enzyme-linked immunosorbent assay; UC
urothelial cancer.
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the RFC is obtained by combining the individual votes
(classifications) of all individual trees, that is, by a major-
ity vote [19,20]. We used the biomarker clusters to esti-
mate the effective dimension of a feature set for the
classification of the patient subpopulations. Each RFC
was, therefore, constructed using one biomarker from
each of the seven biomarker clusters. We estimated the
area under the receiver operating characteristic curve
(AUROC) by using out-of-bag samples, which means
that the trees of a RFC were trained with bootstrap data
which omit approximately one-third of the cases each
time a tree is trained. These samples, called out-of-bag
samples, are used as test data sets to estimate the classifi-
cation errors [19].
As a benchmark, we first determined the classification
error and the AUROC of RFCs with 1,000 trees for all pos-
sible collectives of biomarkers for the total population,
that is, 157 patients. Second, we determined classification
errors and AUROCs for RFCs for each of the three largest
natural patient clusters. Third, we determined classifica-
tion errors and AUROCs of RFCs for 14 clinically defined
subpopulations of patients.
We assumed that clusters/subpopulations with similar
contributory biomarkers to their classifiers were more
homogeneous than subpopulations with different contrib-
utory biomarkers. On this basis, we compared contribu-
tory biomarkers to the RFCs for the three largest patient
clusters and also compared contributory biomarkers
across the split patient populations. For example, we com-
pared the biomarkers that contributed to the RFC for the
101 smokers to the biomarkers that contributed to the
RFC for the 56 non-smokers. Similarly, we compared bio-
markers that contributed to RFCs across gender, history of
stone disease, history of BPE, anti-hypertensive medica-
tion, anti-platelet medication, and anti-ulcer medication.
Results and discussion
Non-random distribution of final diagnoses across patient
clusters
When we clustered the 157 patients on the basis of their
individual patient biomarker profiles, this resulted in five
patient clusters (Figure 1). We observed that the final
diagnosis categories were non-randomly distributed
across the patient clusters (Figure 2A).
Non-random distribution of cancer-risk characteristics
across patient clusters
Further, we observed that the red, purple and gold
patient clusters illustrated in Figure 1, were enriched
with patients with ‘high cancer-risk’ characteristics
[2,4,21]. Conversely, the blue and green patient clusters
were enriched with patients with ‘low cancer-risk’ char-
acteristics (Figure 2). On the basis of these observations
we designated the red, purple and gold natural patient
clusters as ‘high-risk’ and the blue and green patient
clusters as ‘low-risk’.
Prior to chi-square analyses we grouped the ‘no diagno-
sis’, ‘benign pathologies’, ‘stones and inflammation’ and
‘BPE’ categories together as non-life threatening diag-
noses. Similarly, we grouped the cancer patients, that is,
‘other cancers’, ‘NMI UC’ and ‘MI UC’ together as life
threatening diagnoses (Table 1). There was a significant
difference in life threatening diagnoses between ‘low-risk’
and ‘high-risk’ patient clusters (45.3% versus 74.5%, P =
0.001). In addition, there were significant differences in
proteinuria (8.5% versus 70.6%, P <0.001); MI UC (6.5%
versus 44.1%, P = 0.001); grade 3 UC (31.1% versus
63.6%, P = 0.006); and malignant cytology (14.1% versus
48.9%, P = 0.001) between ‘low-risk’ and ‘high-risk’
patient clusters (Figure 2).
In Figure 2, the yellow bars represent ‘low cancer-risk’
characteristics, that is, ‘no diagnosis’, ‘benign pathology’,
‘<0.25 mg/ml total urinary protein’, ‘pTa stage UC’ and
‘grades 1 and 2 UC’. In contrast, the dark brown bars
represent ‘high cancer-risk’ characteristics, that is, ‘other
cancers’, ‘NMI UC’, ‘MI UC’, ‘proteinuria’, ‘≥ pT2 stage
UC’ and ‘Grade 3 UC’. There were proportionately more
patients in the yellow bars in the blue and green patient
clusters in comparison to the proportions recorded
within yellow bars within the red, purple and gold patient
clusters. In Figure 2A, 30/36 (83%) patients with a final
diagnosis of ‘no diagnosis’ fell within the ‘low-risk’ patient
clusters. In the ‘high-risk’ patient clusters, 15/51 (29%)
patients were in the ‘MI UC’ final diagnosis category
(dark brown bars) (Figure 2A). We speculate that the six
patients with a final diagnosis of ‘no diagnosis’ who clus-
tered into the ‘high-risk’ patient clusters, could have
undetected serious disease, for example, kidney disease
[22,23] or another cancer. Unfortunately, we could not
explore this possibility because we did not have ethical
approval to follow-up the patients. In Figure 2B, 97/106
(92%) patients in the ‘low-risk’ patient clusters had nor-
mal urinary protein levels (yellow bars). In contrast, in
the ‘high-risk’ patient clusters, 36/51 (71%) patients had
proteinuria (dark brown bars) (Figure 2B). Ideally, hema-
turic patients with significant proteinuria should be
referred to nephrology [21] to be investigated for kidney
disease [21-23]. In Figure 2C, pathological stages are
represented by bars from left to right, that is, starting
with pTa (yellow bars) and progressing through to dark
brown bars (pT3/pT4 stage UC). Although 28 patients
within the ‘low-risk’ blue cluster and 18 patients in the
‘low-risk’ green cluster had UC, 18/28 (64%) and 16/18
(89%) of these UC, respectively, were stage pTa (yellow
bars) (Figure 2C). Further, 15/18 (73%) pTa tumors in
the blue cluster and 14/16 (88%) pTa tumors in the
green cluster were ≤ pTaG2, that is, very low risk tumors
[2]. Forty-four percent, that is, 15/34 of the UC patients
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Figure 1 Hierarchical clustering of the 157 patients based on individual patient biomarker profiles. Hierarchical clustering of the
157 patients, on the basis of individual patient biomarker profiles, identified five distinct patient clusters as illustrated in this dendrogram. These
clusters have (from top to bottom) 57 (28) (blue), 13 (8) (red), 49 (18) (green), 15 (11) (purple) and 23 (15) (gold) patients in each cluster. The
number in brackets is the number of patients with urothelial cancer (UC) in the corresponding cluster. UC and control patients were evenly
distributed across the five patient clusters. Pclass = 1 corresponds to control patients, that is, hematuric patients who were negative for
investigations for UC. Pclass = 2 corresponds to UC patients.
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in the red, purple and gold clusters had tumors ≥ pT2,
which would be deemed high-risk [4] (brown bars)
(Figure 2C). As we have previously discussed, there is
molecular heterogeneity within the same tumor stage
and it is possible that some of the pT1 and CIS tumors
falling within the red, purple and gold clusters could
have predisposing molecular profiles for progression.
Further, it is important to emphasize that the division of
UC tumors into NMI and MI is arbitrary and perhaps too
simplistic. For example, there will be a significant differ-
ence in risk between a pT1 tumor with minimal submuco-
sal invasion and a pT1 tumor with extensive submucosal
invasion with the concomitant risk of lymphovascular
invasion. Grade reflects the degree of differentiation within
A B
C D
Final diagnosis categories Total protein in urine
Pathology gradePathology stage
Figure 2 Cancer-risk characteristics across the patient clusters. The final diagnosis categories were non-randomly distributed across the five
patient clusters identified in Figure 1. The blue and green patient clusters were significantly enriched for patients with ‘low cancer-risk’
characteristics (bars in yellow) while the red, purple and gold clusters were significantly enriched for patients with ‘high cancer-risk’
characteristics (bars in dark brown). (A) The patient counts, from left to right, within ‘no diagnosis’, ‘benign pathologies’, ‘stones and
inflammation’, ‘benign prostate enlargement’ (BPE), ‘other cancers’, ‘non-muscle invasive urothelial cancer’ (NMI UC) and ‘muscle invasive
urothelial cancer’ (MI UC) are illustrated for each of the five patient clusters. Following agglomerative clustering 30/36 (83%) patients within the
‘no diagnosis’ category were in either the blue or green patient clusters (yellow bars). (B) The numbers of patients with normal protein levels are
shown by yellow bars. Most patients with normal protein levels fell within the blue (54/112 (48%)) and green clusters (43/112 (38%)). (C) The
numbers of patients with pTa stage UC are shown by yellow bars. Within the blue and green patient clusters, 18/28 (64%) and 16/18 (89%),
respectively, of the patients with UC had pTa disease (yellow bars). In contrast, when the red, purple and gold patient clusters were combined,
16/34 (47%) of the UC patients had high stage disease (dark brown bars). (D) The number of patients with Grade 3 UC is shown by dark brown
bars. Within the red, purple and gold patient clusters 5/7 (71%), 7/11 (64%), and 9/15 (60%), respectively, had Grade 3 UC. In comparison, 10/27
(37%) and 4/18 (22%), respectively, in the blue and green patient clusters had grade 3 UC (dark brown bars).
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a tumor. When we explored the pathological grades of
the UC tumors, 21/33 (64%) UC patients in the ‘high-
risk’ patient clusters had grade 3 disease (dark brown
bars) compared to 14/45 (31%) in the ‘low-risk’ clusters
(Figure 2D). In addition, we found that there were signif-
icant differences in malignant cytology (14.1% versus
48.9%, P = 0.001) between ‘low-risk’ and ‘high-risk’
patient clusters.
Reduction of the complexity of the biomarker data
We used hierarchical clustering to identify the most infor-
mative set of biomarkers for use as feature vectors for UC
diagnostic classifiers. Hierarchical clustering identified
seven biomarker clusters consisting of Nb = (2, 2, 6, 5, 4, 3,
7) biomarkers (Figure 3). We assumed that biomarkers
within individual clusters would contain redundant bio-
logical information about the patients and that it was
sufficient to select one biomarker to represent each clus-
ter. Overall, this provided us with a systematic way to esti-
mate the number of representative biomarkers, which
could be considered as the effective dimension of the
biomarker-space. From this it follows that the total
number of combinations is only 10,080 as given by
NC =
7∏
i=1
Nb(i) = 10080
each corresponding to a 7-tuple of biomarkers. Hence, the
grouping of biomarkers into seven groups broke down the
combinatorial complexity of the overall problem, allowing
us to conduct an exhaustive search in this constraint set of
biomarkers. In contrast, an unconstrained, exhaustive search
would not have been feasible because the number of uncon-
strained feature combinations for up-to 7-dimensional fea-
ture vectors is larger than 2.1 million, as given by
NT(29) =
29∑
k=1
(
29
k
)
(
29
k
)
is the binomial coefficient.
This is more than two orders of magnitude larger than
NC making an exhaustive search computationally infeasible.
For all possible NC = 10,080 biomarker combinations,
we determined the classification error and the AUROC of
RFCs for each of the following: (1) all the 157 patients, (2)
the three largest patient clusters from Figure 1, and (3) 14
subpopulations which were split on the basis of clinical or
demographic parameters.
Contributory biomarkers to UC diagnostic classifiers for
the low-risk patient clusters were similar
Only two of the patient clusters, those shown in blue and
green in Figure 1, contained sufficient numbers, that is, 57
and 48, to train a RFC. However, for reasons of compari-
son, we also trained a RFC for the gold cluster, which con-
tained 23 patients, 15 of whom were diagnosed with UC
(Figure 2). We found that 4/7 biomarkers were the same
in the diagnostic classifiers for the blue and green patient
clusters suggesting that these patient clusters had biologi-
cal similarities. This is interesting because we had desig-
nated patients within both of these clusters as ‘low-risk’.
Further, only 2/7 and 1/7 of the biomarkers, which con-
tributed to the blue and green low-risk clusters, respec-
tively, also contributed to the classifier for the gold cluster.
This would suggest that the gold patient cluster had signif-
icantly different underlying biological properties in com-
parison to the blue and green clusters. These observations
would concur with our risk stratification hypothesis. The
standard deviation of the classification error and of the
AUROC for this smaller gold cluster, in comparison to the
blue and green patient clusters, increased by approxi-
mately 30 % (Table 3).
Contributory biomarkers to UC diagnostic classifiers
across clinically split patient subpopulations were
different
When we determined classification errors and AUROCs
of UC diagnostic RFCs for 14 clinically defined subpo-
pulations we observed the highest AUROC = 0.843
(averaged over 100 repetitions) in the classifier for
patients not taking anti-platelet medication (n = 118).
For the clinically split subpopulations, we found that
when specific biomarkers contributed to the UC diag-
nostic RFC for one clinically relevant subpopulation,
they were less likely to contribute to the RFC for the
complementary subpopulation. For example, compare
the biomarkers across patient subpopulations taking
anti-platelet medication to those not on the medication
(Table 3).
Biomarkers associated with inflammatory conditions
predominated two of the biomarker clusters
Biomarkers associated with inflammatory conditions
predominated the black and brown biomarker clusters
(Figure 3). The black cluster contained C-reactive protein
(CRP) and TNFa. The brown cluster comprised D-dimer,
interleukin-1a, interleukin-1b, neutrophil-associated gela-
tinase lipocalin (NGAL) and total urinary protein. The lat-
ter five biomarkers were significantly elevated in urine
from patients in the ‘high-risk’ patient clusters (Mann
Whitney U, P <0.001) (Table 4). NGAL is expressed by
neutrophils and its main biological function is inhibition
of bacterial growth [24]. NGAL, being resistant to degra-
dation, is readily excreted in urine, both in its free form
and in complex with MMP-9, which may protect it from
degradation [24]. NGAL is also a useful biomarker of
acute kidney disease [23]. Since the prevalence of kidney
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disease is one in six adults [25], NGAL should perhaps be
an important consideration in urinary biomarker studies
on patient populations which include high proportions of
patients >50 years old. In our analyses, significantly higher
NGAL levels were recorded in the purple patient subpo-
pulation (1,379 ng/ml), 14/15 of whom had cancer, com-
pared to levels measured in the patients in the gold group
(464 ng/ml) (Table 4) who had a greater diversity of final
diagnoses (Figure 2A) (Mann Whitney U; P = 0.012).
Median EGF levels were significantly higher in the gold
patient cluster (14 µg/ml) in comparison to the purple
patient cluster (4 µg/ml) (Mann Whitney U; P <0.001)
(Table 4). Interestingly, 9/23 patients in the gold patient
cluster had ≥ pT1G3 UC and the purple patient cluster
included cancers other than UC (Figure 2). Bladder cancer
risk and survival have been associated with genetic varia-
tion in the Epidermal growth factor receptor (EGFR) path-
way [26].
Translation of risk and diagnostic classifiers from systems
biology to the clinic
We have described how hierarchical clustering, conducted
on the basis of individual patient biomarker profiles, iden-
tified patient clusters and how cancer-associated risk char-
acteristics were non-randomly distributed across these
clusters (Figures 1 and 2 and Tables 5, 6, 7, 8, 9, 10).
These findings suggest that it should be possible to define
risk classifiers which could be informative at the point of
triage of hematuric patients. This approach could have the
potential to significantly improve healthcare outcomes for
patients with hematuria.
Biochip array technology [17] allows rapid and simulta-
neous measurement of the levels of multiple biomarkers.
This technology will facilitate the translation of protein-
based classifiers, as described in this manuscript, from the
laboratory to the clinic [27]. Antibodies, raised against bio-
markers contributing to an individual classifier, can be
Figure 3 Hierarchial clustering of the 29 biomarkers. This dendrogram illustrates seven distinct biomarker clusters containing (from left to
right): 2 (black), 2 (green), 6 (purple), 5 (gold), 4 (pink), 3 (blue) and 7 (yellow) biomarkers each. Two of the biomarker clusters comprised
predominantly inflammatory proteins. For example, the brown cluster comprised D-dimer, interleukin-1a (IL-1a), interleukin-1b (IL-1b), neutrophil-
associated gelatinase lipocalin (NGAL) and total protein. BTA, bladder tumor antigen; CEA, carcino-embryonic antigen; CK18, cytokeratin 18; CRP,
C-reactive protein; EGF, epidermal growth factor; FPSA, free prostate specific antigen; HA, hyaluronidase; MCP-1, monocyte chemoattractant
protein-1; MMP-9, matrix metalloproteinase 9; NSE, neuron specific enolase; sTNFR1, soluble TNF receptor 1; TM, thrombomodulin; TNFa, tumor
necrosis factor a; VEGF, vascular endothelial growth factor; vWF, von Willeband factor.
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formatted onto a single biochip. We predict that risk strati-
fication biochips and UC diagnostic biochips could be
created and validated in the near future [28]. In clinical
practice, scores between 0 and 1, from the risk and
diagnostic UC biochips would make it possible to designate
each patient with hematuria as a ‘low-risk control’, a
‘high-risk control’, a ‘low-risk UC’ or a ‘high-risk UC
(Figure 4). Scores <0.4 obtained using the risk biochip
would suggest that the likelihood of serious disease was
low. Similarly, a score <0.4 obtained using the UC diagnos-
tic biochip would suggest that it was unlikely that the
patient had UC. In contrast, scores >0.6 from the risk or
Table 3 Random Forest Classifiers for patient clusters and clinical subpopulations.
Variable description Sub populations Biomarkers Classification error (SD) AUROC (SD)
All 157 hematuria patients controls n = 77
UC n = 80
CRP, EGF, IL-6, IL-1a, MMP9NGAL, osmolarity, CEA 0.203 (0.017) 0.766 (0.152)
Patient clustersa blue
n = 57 (28)
TNFa, EGF, NSE, NGAL, MMP9NGAL, TM, FAS 0.155 (0.029) 0.800 (0.258)
green
n = 49 (18)
TNFa, EGF, IL-6, IL-1a, MMP9NGAL, TM, CEA 0.204 (0.037) 0.825 (0.264)
gold
n = 23 (15)
CRP, sTNFR1, vWF, IL-1a, MMP9NGAL, creatinine, BTA 0.245 (0.049) 0.700 (0.349)
Clinical subpopulations
Smoking smokers
n = 101 (60)
CRP, EGF, MMP9, IL-1a, IL-4, TM, IL-2 0.276 (0.027) 0.770 (0.117)
non- smokers
n = 56 (20)
TNFa, sTNFR1, IL-6, IL-1a, MMP9NGAL, creatinine, CEA 0.156 (0.027) 0.783 (0.159)
Gender males
n = 120 (65)
CRP, EGF, CK18, IL-1b, IL-8, creatinine, IL-2 0.272 (0.030) 0.753 (0.117)
females
n = 37 (15)
CRP, EGF, IL-6, dDimer, MMP9NGAL, osmolarity, CEA 0.181 (0.054) 0.830 (0.146)
Hx stone disease yes
n = 30 (14)
CRP, sTNFR1, CK18, IL-1a, IL-8, creatinine, VEGF 0.322 (0.062) 0.738 (0.194)
no
n = 127 (66)
CRP, EGF, IL-6, IL-1a, MMP9NGAL, creatinine, CEA 0.186 (0.015) 0.817 (0.117)
Hx BPE yes
n = 30 (14)
CRP, EGF, IL-6, IL-1a, MMP9NGAL, TM, CEA 0.192 (0.018) 0.826 (0.148)
no
n = 127 (66)
CRP, EGF, CK18, NGAL, MMP9NGAL, creatinine, BTA 0.266 (0.061) 0.788 (0.169)
Anti-hypertensive medication on medication
n = 73 (51)
TNFa, EGF, IL-6, protein, MMP9NGAL, creatinine, CEA 0.211 (0.025) 0.731 (0.161)
no medication
n = 83 (28)
TNFa, sTNFR1, IL-6, NGAL, IL-8, TM, CEA 0.145 (0.028) 0.810 (0.132)
Anti-platelet medication on medication
n = 37 (25)
TNFa, EGF, IL-6, protein, IL-8, osmolarity, CEA 0.215 (0.019) 0.780 (0.141)
no medication
n = 118 (53)
CRP, EGF, MCP-1, protein, MMP9NGAL, TM, FPSA 0.160 (0.046) 0.843 (0.153)
Anti-ulcer medication on medication
n = 33 (17)
CRP, EGF, IL-6, IL-1a, IL-8, TM, CEA 0.220 (0.018) 0.827 (0.118)
no medication
n = 123 (62)
CRP, EGF, vWF, IL-1b, MMP9NGAL, TM, HA 0.259 (0.072) 0.812 (0.168)
Using the clusters of biomarkers as a feature set, we determined the classification error and the area under the receiver operating characteristic curve (AUROC) of
urothelial cancer (UC) diagnostic classifiers for all possible biomarker combinations for all 157 hematuria patients; for 3/5 of the patient clusters; and for 14
subpopulations split on the basis of smoking, gender, history of stone disease, history of benign prostate enlargement (BPE), or anti-hypertensive, anti-platelet or
anti-ulcer medications. Therefore, one biomarker from each of the seven clusters illustrated in the biomarker dendrogram (Figure 3), was represented in each
classifier. The classification errors in the clinically split populations were very similar to those obtained for the patient clusters. aOnly two of the natural patient
subpopulations, those shown in blue and green in Figure 1, contained sufficient numbers to train a Random Forest Classifier (RFC). For reasons of comparison, we
also trained a RFC for the gold cluster. Four of the seven biomarkers were the same in the diagnostic classifiers for the blue and green patient clusters suggesting
biological similarities. The numbers in brackets in the second column indicate the number of patients with UC. BTA, bladder tumor antigen; CEA, carcino-embryonic
antigen; CK18, cytokeratin 18; CRP, C-reactive protein; EGF, epidermal growth factor; FPSA, free prostate specific antigen; IL, interleukin; HA, hyaluronidase; MMP-9,
matrix metalloproteinase 9; NGAL, neutrophil-associated gelatinase lipocalin; NSE, neuron specific enolase; SD, standard deviation; sTNFR1, soluble tumor necrosis
factor receptor 1; TM, thrombomodulin; TNFa, tumor necrosis factor a; VEGF, vascular endothelial growth factor; vWF, Von Willeband factor.
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diagnostic biochip would be suggestive of serious disease or
UC, respectively. Scores between 0.4 and 0.6 could be inter-
preted as indicative of potential risk and the possibility of
UC.
If specificities and sensitivities for both biochips were
>90%, this would mean a high-risk cancer patient would
have a 1:10 chance of being wrongly classified as low-risk
and subsequently a 1:10 chance of being wrongly classified
as a control. In this scenario, out of 1,000 high-risk cancer
patients approximately 810 would be correctly classified as
high-risk cancers, approximately 90 as high-risk controls,
approximately 90 as low-risk cancers and approximately
Table 4 Median biomarker levels in patient clusters.
Biomarker (units) Median (inter quartile range) in patient clusters
blue red green purple gold
BLACK CLUSTER
CRP (ng/ml) 1.05 (0.74 to 1.33) 0.86 (<0.67 to 0.91) 1.06 (0.84 to 1.25) <0.67 (<0.67 to 0.83) 0.75 (<0.67 to 0.90)
TNFa (pg/ml) 10.52 (7.78 to 13.25) 9.07 (7.36 to 9.79) 9.54 (7.46 to 11.78) 11.66 (8.95 to 15.48) 10.20 (8.31 to 12.820)
GREEN CLUSTER
EGF (pg/ml) 7,056 (4,965 to 13,752) 3,633 (1,874 to 5,992) 6,477 (2,784 to 10,943) 3,722.33 (3,058 to 4,956) 13,826 ( 9,488 to 20,332)
sTNFR1(pg/ml) 0.67 (0.41 to 1.04) 0.75 (0.47 to 1.05) 0.57 (0.24 to 1.61) 0.74 (0.45 to 1.06) 1.60 (0.97 to 2.54)
PURPLE CLUSTER
CK18 (ng/ml) 2.30 (0.71 to 3.59) 1.22 (0.42 to 2.78) 2.03 (0.75 to 4.33) 8.97 (2.88 to 21.43) 6.43 (2.67 to 10.28)
MCP-1 (pg/ml) 112 (38 to 212) 73 (41 to 141) 67 (28 to 113) 269 (118 to 871) 237 (106 to 550)
NSE (ng/ml) IQR below LOD 0.28 (<0.26 to 0.92) IQR below LOD 1.72 (<0.26 to 18.32) 0.51 (< 0.26 to 2.37)
MMP-9 (ng/ml) IQR below LOD IQR below LOD IQR below LOD 15.15 (6.57 to 50.81) IQR below LOD
IL-6 (pg/ml) 1.37 (<1.20 to 3.60) 12.93 (3.27 to 26.67) <1.20(<1.20 to 2.50) 194.33 (16.43 to 577.33) 40.80 (4.80 to 196.67)
vWF (IU/ml) purple 0.01 (0.01 to 0.02) 0.01 (0.00 to 0.01) 0.01 (0.01 to 0.01) 0.01 (0.01 to 0.02) 0.01 (0.01 to 0.03)
GOLD CLUSTER
Protein (mg/ml) 0.07 (0.05 to 0.11) 0.44(0.29 to 0.60) 0.08 (0.05 to 0.12) 0.59 (0.25 to 0.93) 0.30 (0.09 to 1.00)
NGAL (ng/ml) 123 (92 to 212) 192 (146 to 297) 110 (74 to 148) 1,379 (602 to 1922) 464 (108 to 1368)
D-dimer (ng/ml) <2.10 (<2.10 to 5.02) 47.01 (11.80 to 138.27) <2.10 (<2.10 to 3.62) 597.89 (62.16 to 1493.69) 58.35 (<2.10 to 559.38)
IL-1a (pg/ml) 0.90 (0.90 to 2.52) 2.42 (1.01 to 3.53) 0.90 (0.90 to 1.01) 21.35 (5.80 to 30.93) 2.47 (0.90 to 81.00)
IL-1b (pg/ml) IQR below LOD IQR below LOD IQR below LOD 17.80 (5.46 to 78.87) <1.60 (<1.60 to 19.12)
PINK CLUSTER
IL-8 (pg/ml) 32.40 (7.93 to 265.83) 292.67 (117.33 to 604.33) 28.63 (7.90 to 135.33) 2,900 (2,064 to 2,900) 875.67 (48.40 to 2,900)
MMP9NGAL 0.09 (0.08 to 0.10) 0.16 (0.10 to 0.29) 0.07 (0.07 to 0.09) 0.29 (0.23 to 0.48) 0.23 (0.09 to 0.29)
IL-4 (pg/ml) IQR below LOD IQR below LOD IQR below LOD <6.60 (<6.60 to 6.80) IQR below LOD
sTNFR2 (pg/ml) IQR below LOD <0.15 (<0.15 to 0.26) <0.15 (<0.15 to 0.26) IQR below LOD <0.15 (<0.15 to 0.61)
BLUE CLUSTER
creatinine (µmol/L) 9,608 (7,961 to 13,360) 5,605 (4,454 to 11,945) 7,115 (3,868 (12,595) 7,600 (5,360 to 8,625) 14,087 (12,405 to 17,245)
osmolarity (mOsm) 536 (450 to 741) 462 (276 to 560) 526 (278 to 675) 404 (314 to 482) 644 (567 to 7,840)
TM (ng/ml)blue 4.08 (3.19 to 4.97) 3.97 (1.55 to 5.69) 4.00 (1.74 to 5.68) 3.49 (2.65 to 4.00) 6.30 (5.34 to 8.86)
YELLOW CLUSTER
IL-2 (pg/ml) 5.61 (5.21 to 5.92) 5.24 (5.02 to 5.65) 5.45 (5.20 to 6.27) 6.89 (5.99 to 7.24) 5.99 (5.65 to 7.20)
CEA (ng/ml) 1.57 (1.16 to 2.58) 1.59 (1.15 to 3.23) 1.36 (0.87 to 2.10) 1.77 (1.30 to 2.39) 1.37 (0.89 to 2.80)
HA (ng/ml) 685 (439 to 866) 835 (595 to 1005) 594 (282 to 900) 1,569 (1,143 to 1,846) 1,258 (883 to 1,712)
FPSA (ng/ml) 0.09 (0.04 to 0.21) 0.05 (0.04 to 0.23) 0.07 (0.04 to 0.12) 0.13 (0.07 to 0.30) 0.05 (0.04 to 0.10)
BTA (U/ml) 8.52 (2.57 to 38.96) 248.01 (206.82 to 394.15) 6.27 (1.21 to 17.92) 278.41 (226.40 to 504.33) 213.00 (15.24 to 476 .28)
VEGF (ng/ml) 88 (37 to 271) 96 (76 to 220) 78 (38 to 122) 1,266 (414 to 1,500) 253 (79 to 621)
FAS (pg/ml) 64 (42 to 96) 83 (60 to 128) 56 (37 to 86) 214 (106 to 475) 200 (96 to 279)
The median level and the inter-quartile range (IQR) of each biomarker in each patient cluster are shown. The biomarkers are grouped vertically to reflect how
they appear in the biomarker cluster dendrogram (Figure 3). BTA, bladder tumor antigen; CEA, carcino-embryonic antigen; CK18, cytokeratin 18; CRP, C-reactive
protein; EGF, epidermal growth factor; FPSA, free prostate specific antigen; HA, hyaluronidase; IL, interleukin; LOD, limit of detection; MCP-1, monocyte
chemoattractant protein-1; MMP-9, matrix metalloproteinase 9; NGAL, neutrophil-associated gelatinase lipocalin; NSE, neuron specific enolase; sTNFR1, soluble
tumor necrosis factor receptor 1; sTNFR2, soluble tumor necrosis factor receptor 2; TM, thrombomodulin; TNFa, tumor necrosis factor a; VEGF, vascular
endothelial growth factor; vWF, Von Willeband factor.
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Table 5 Final diagnoses across the patient clusters.
patient clusters final diagnosis categories total
no diagnosis benign pathologies stones and/orinflammation BPE other cancers NMI UC MI UC
blue 16 1 6 6 0 26 2 57
red 3 0 1 1 0 5 3 13
green 14 5 6 4 2 17 1 49
purple 0 0 0 1 3 7 4 15
gold 3 0 4 0 1 7 8 23
BPE, benign prostate enlargement; MI UC, muscle invasive urothelial cancer; NMI UC, non-muscle invasive urothelial cancer.
Table 6 Total urinary protein across the patient clusters.
patient clusters total urinary protein (mg/ml) total
<0.25 >0.25
blue 54 3 57
red 2 11 13
green 43 6 49
purple 3 12 15
gold 10 13 23
Table 7 Pathology stages of the urothelial carcinomas across the patient clusters.
patient clusters pathology stage total
pTa pT1 pT2a pT2b pT3a pT3b pT4a CIS
blue 18 7 1 0 0 0 1 1 28
red 3 1 3 0 0 0 0 1 8
green 16 1 1 0 0 0 0 0 18
purple 5 2 2 2 0 0 0 0 11
gold 5 2 3 0 1 3 1 0 15
CIS, carcinoma in situ.
Table 8 Pathology grades of the urothelial carcinomas across the patient clusters.
patient clusters pathology grade total
grade 1 grade 2 grade 3
blue 2 15 10 27
red 0 2 5 7
green 0 14 4 18
purple 1 3 7 11
gold 1 5 9 15
Table 9 Cytology diagnosis across the patient clusters.
patient clusters cytology total
no evidence of malignancy malignant
blue 38 11 49
red 7 6 13
green 41 2 43
purple 8 6 14
gold 9 11 20
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Table 10 Pathological grades of the Ta stage urothelial carcinomas across the patient clusters.
patient clusters pathology grades in pTa tumors total
grade 1 grade 2 grade 3
blue 2 13 3 18
red 0 2 1 3
green 0 14 2 16
purple 1 3 1 5
gold 1 3 1 5
Haematuria
patients
Risk groupings
Drop of urine/serum
from each patient
applied onto Risk biochipScore > 0.6
High Risk
Score < 0.4
Low Risk
Risk
biochip
High risk 
cancers
Low risk 
cancers
Low risk 
controls
High risk 
controls
Patient groups to 
inform triage 
decisions
Score < 0.4
Drop of urine/serum
applied onto 
Diagnostic  UC biochip
Score > 0.4Score > 0.6 Score > 0.4Diagnostic biochip
Figure 4 Translation of classifiers into biochip format for risk stratification of hematuria patients. In the future when a patient with
hematuria presents in primary care, their urine and serum samples could be sent for evaluation using biochips (grey oblongs). One biochip
could be created for risk stratification and one biochip for the diagnosis of UC. Each biochip would be formatted with approximately six
antibody spots, referred to as test regions. The underlying concept of these biochips is based on procedures similar to an ELISA, that is, light
readings are generated from each test region which are proportional to the bound protein that is present in each patient’s sample. Computer
software would generate a score between 0 and 1 for each patient’s sample. For the risk biochip, scores <0.4 would suggest a low risk of
serious disease, while scores >0.6 would suggest a high risk of serious disease. The patient could then be designated low-risk (green) or high-risk
(red) risk. Patients would then be screened using a second biochip, this time a UC diagnostic biochip. Similarly, scores <0.4 from the UC
diagnostic biochip would suggest that it was unlikely that the patient would have bladder cancer while scores >0.6 would suggest that the
patient requires further investigations to check for the presence of UC. The scores from both biochips would be interpreted alongside clinical
parameters. The patient’s clinician would then make a triage decision for that patient which would be informed by the biochip scores. For
example, a high-risk UC patient (all red) could obtain a score >0.6 on the scale ranging from 0 to 1 for both biochips and likewise a low-risk
control could receive a score <0.4 for both biochips. ELISA, enzyme-linked immunosorbent assay; UC, urothelial cancer.
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10 as low-risk controls (Figure 4). Following biochip
analyses, patients with scores ≤0.2 from both biochips and
no clinical risk factors, that is, low-risk controls, could be
monitored in primary care. This would lead to a reduction
in the number of cystoscopies in these patients. In another
scenario, a proportion of patients might be assigned as
high-risk control patients following analyses of their sam-
ples using the biochips. These patients should be investi-
gated further because they could have other diseases, for
example, kidney disease which could then be managed
appropriately [21]. In this way, improved triage would
result in expeditious diagnosis for a greater proportion of
patients with hematuria who would then receive earlier
and more effective therapeutic interventions. This would
represent a significant healthcare improvement [29].
Single biomarkers have failed to be diagnostic for hema-
turia and many other complex diseases. Panels of biomar-
kers, in addition to clinical information, provide a large
array of patient data that can be highly informative and
have potential for diagnostic and prognostic decision mak-
ing. However, the difficulties to date with large amounts of
patient biomarker data are that they do not manage or
group all patients in a clinically meaningful way. Systems
biology is a developing technology [30] that has evolved
new and different ways to analyze very large and complex
datasets, such as those relating to sequencing of the gen-
ome and those collected from complex diseases. We have
described how patients with hematuria naturally cluster
into risk groupings on the basis of their individual biomar-
ker profiles. This challenges the current practice in hema-
turia clinics which prioritizes diagnosis of patients with
bladder cancer. Patients in the ‘high-risk’ clusters included
controls, that is, patients without bladder cancer. However
these ‘controls’ may have other cancers or may have neo-
plasms at very early stages of carcinogenesis, that is, below
the size threshold for detection. Because cystoscopy is not
a perfect diagnostic tool and because there is an urgent
need to identify all patients with serious disease at the
hematuria clinic, the findings in this paper represent a sig-
nificant advance in the approach to triage and diagnosis of
hematuria patients.
Conclusions
When we clustered patients with hematuria on the basis of
their individual patient biomarker profiles, we identified
five patient clusters. We observed that the final diagnoses
for the 157 patients with hematuria were non-randomly
distributed across these patient clusters. Other ‘high can-
cer-risk’ characteristics, that is, proteinuria, pathological
stage, pathological grade and malignant cytology were also
non-randomly distributed across the patient clusters.
Indeed, we identified three patient clusters that were
enriched with patients who harbored ‘high cancer-risk’
characteristics and two patient clusters that were enriched
with patients with ‘low cancer-risk’ characteristics. These
findings indicate the feasibility of creating risk classifiers
that could inform the triage of patients with hematuria.
Risk classifiers could improve decision-making at the
point of triage. This would result in a more accurate and
timely diagnosis for patients with serious disease thus
improving outcomes for a greater proportion of patients
[1,2,29].
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